Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

JUNSBullishCorporate Developmentsnews

High materiality9/10

Jupiter Neurosciences expands CNS pipeline with ALA-002 license from PharmAla

Jul 21, 2026, 7:15 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The deal adds a second late-stage CNS asset with clear milestones, potential royalties, and US-only rights, supported by favorable psychedelic-regulatory headlines, likely prompting reevaluation of JUNS's risk-reward and near-term upside.

AI summary

What happened, with direct paths to the underlying reporting

Jupiter Neurosciences announced a definitive license with PharmAla to secure perpetual exclusive U.S. rights to ALA-002, a patented non-racemic MDMA NCE. The deal broadens JUNS into a dual CNS platform alongside JOTROL and Nugevia, with near-term milestones, royalties, and potential regulatory acceleration under new policy measures for psychedelic therapies.

Jupiter signs license for ALA-002 with PharmAla. Up to $100M value.
Upfront $3.3M: $1.5M cash plus $1.8M JUNS stock; 120-day lock-up.
Milestones include Phase 3 First Patient In and NDA regulatory milestone $20M.
ALA-002 is FDA NCE-designated non-racemic MDMA; perpetual US rights.
Regulatory shift under 2026 executive order may accelerate psychedelic therapies.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Jupiter Neurosciences expands CNS pipeline with ALA-002 license from PharmAla

Jupiter Neurosciences Gains from PharmAla Patent Grant and Partner Updates

Jupiter Neurosciences Acquires ALA-002 Rights, Boosting Growth Potential